People · Operator

Ronald Yamamoto

Named in public records as an officer, director or promoter · active 2012–2012 · Biotechnology

1
Companies
1
Filings
$13.8M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Halscion IncBiotechnologySeries A$13.8M$155.4M2012
Operator network

Ronald Yamamoto at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Anthony Lando · 6 companies · 1 sharedAnthony LandoGerard Van Hamel Platerink · 6 companies · 1 sharedGerard Van Hamel …James Garvey · 6 companies · 1 sharedJames GarveyCharles Warden · 5 companies · 1 sharedCharles WardenGerard B. Van Hamel Platerink · 2 companies · 1 sharedGerard B. Van Ham…Kathleen Beauchamp · 2 companies · 1 sharedKathleen BeauchampRon Yamamoto · 2 companies · 1 sharedRon YamamotoSamuel B. Wu · 2 companies · 1 sharedSamuel B. WuAnthony B. Lando · 1 companies · 1 sharedAnthony B. LandoCharles B. Warden · 1 companies · 1 sharedCharles B. WardenJonathan Wyler · 1 companies · 1 sharedJonathan WylerRobert Leslie · 1 companies · 1 sharedRobert LeslieSteven B. Waite · 1 companies · 1 sharedSteven B. WaiteThomas B. Weldon · 1 companies · 1 sharedThomas B. WeldonHalscion Inc · $13.8M raisedHalscion IncRonald YamamotoRY
Ronald Yamamoto Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Ronald Yamamoto on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Anthony Lando16
James Garvey16
Gerard Van Hamel Platerink16
Charles Warden15
Ron Yamamoto12
Samuel B. Wu12
Gerard B. Van Hamel Platerink12
Kathleen Beauchamp12
Robert Leslie11
Charles B. Warden11
Steven B. Waite11
Jonathan Wyler11
Anthony B. Lando11
Thomas B. Weldon11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.